Pinned Tweet
FinalDose: We’re going to end cancer in the open
We plan to build FinalDose as public as we possibly can and write up as we go, including the parts that don’t survive! Please help spread the word:
@FinalDoseLFG
substack.com/@finaldose
Jeff Liu retweeted
The pharma folks are right to call out Dario for making bold claims about curing all disease.
They are also right that most necessary bio data does not yet exist.
Still, pharma has two crucial blindspots:
1) The industry has never witnessed what a small, well capitalized, and well incentivized silicon valley team can do (no instagram, whatsapp, ARM, cursor in pharma). They grossly underestimate what's coming for them.
2) They don't yet see just how much the labs *need* to win in bio to double TAM (there simply is not other accessible market), and just how much all of tech's liquidity relies on this happening.
Pharma is a risk management industry: you get fired for failing in old ways, not for failing in new ways. The industry will be shocked at how fast automated labs, better models, etc can be stood up by small, well capitalized teams that have only 1x to lose and thousands of x to gain.
Pharma doesn't quite yet have a traditional innovator's dillema. Their capital and GTM moats are still deep, but not for much longer (drugs going d2c, dev costs decreasing). Pharma's window to win is open, but it will close fast if they fail to take ownership of the incoming infrastructure explosion.
Lets gooo
This letter was sent to Nvidia's board today.
A first for @atreidesmgmt
Absolutely share @altcap belief that this letter outlines minimum acceptable standards.
106
New episode of HARD DRUGS!
Will AI progress be crushed by Eroom’s law?
Even as technology has advanced, drug development has gotten more and more expensive over time.
In the 1950s, one billion dollars of R&D spending got us roughly fifty new drugs. Today, it gets us about one.
This trend is called Eroom’s law, or Moore’s law spelled backwards. It seems pretty bleak: the R&D cost per new drug has roughly doubled every nine years, in inflation-adjusted dollars, meaning drug development has become exponentially more expensive.
What could explain this? Here are some possibilities:
• Our standards of evidence and requirements for safety testing have risen, through regulation, public expectations, and risk aversion.
• We’ve picked the low-hanging fruit already. Perhaps we’ve already made the easiest discoveries, and diseases that are harder to understand or treat are left.
• Or perhaps it’s the ‘better than the Beatles’ problem: New drugs not only have to be effective, but have to compete with existing treatments, which are already effective. Plus, some of them have gone off-patent and become cheap generics, making the price contrast starker.
Relatedly, as diseases become rarer or milder, it takes more effort to demonstrate that new drugs are effective, with larger or longer clinical trials.
But there are also reasons to question these explanations. We still lack effective treatments for many diseases. And our tools for studying biology have improved enormously. Why hasn’t that been enough?
Will our best efforts be crushed by Eroom’s law, too? Or can AI reverse the trend?
In our latest episode of HARD DRUGS, @JacobTref and I chat about all this and more. Listen wherever you get your podcasts!
Chapters:
00:00 Introduction
02:53 Eroom’s law trivia
12:33 How much does it really cost to develop a drug?
22:35 The better than the Beatles problem
33:06 Clinical trials are larger and more rigorous today
42:01 Have we picked the low-hanging fruit?
01:01:22 Is Eroom’s law slowing down because of rare disease drugs?
01:06:18 Can AI reverse Eroom’s law?
01:15:09 Conclusion
Jeff Liu retweeted
I analyzed eleven New York Times reports on the Jensen Huang story.
Most notably, NYT makes the "spy" claim 30 times in these 11 reports.
The original report cites unnamed officials who had been "briefed" on the intelligence. Not who had seen it themselves -- but who had been "briefed".
This is a game of telephone with plausible deniability.
Nobody named. No specific details of the intelligence used to draw the conclusion that the woman was a spy.
Anonymous "officials" "briefed".
This was used to try to take Jensen Huang down.
When that didn't work, journalists resorted to viciously digging up and scandal mongering about Jensen Huang's other alleged affairs.
Then he was removed as CEO.
Without an investigation.
Without due process.
And now officials and intelligence agencies are contesting the New York Times characterization.
This is unethical. It is unjust.
It is an absolute disgrace.
If anyone should resign now, it is Nvidia's board who aggressively removed Jensen Huang without an investigation, after he gave decades of his life to make the company what it is.
And any investigation that proceeds from here should involved not just the "spy" claim, but the New York Times -- who has engaged in potentially unethical behavior.
Jensen Huang deserves due process -- not mob justice.
He deserves respect for everything he has done for technology and America -- not a disgraceful removal after anonymous, unsubstantiated allegations, several parties removed from the source.
Bombshell story. The spy narrative is collapsing already.
Is there clear & convincing evidence that Alice Huang was a Chinese spy?
- AG says no. (“no conclusions reached”).
- CIA says no. (“not yet convinced”).
- DNI says no (“not entirely accurate and over-torqued”).
- Ranking Democrat on House Intelligence (incoming Chairman) says no. (“today, at least, I don’t know”). This was immediately after he was briefed.
Who argues otherwise? Anonymous officials tell CNN “it strains credulity to believe that she was not acting as an agent of the Chinese government — simply by virtue of the fact that she is a successful Chinese businesswoman working with one of America’s most powerful companies.”
This is their proof after a year of investigating and surveillance? That she was a “successful Chinese businesswoman”?
At this point, the only crime that we know for sure happened is the leaking of the classified memo. Who did that and why?
An investigation should be opened.
I stand with him
As the swirl continues (which I believe should be taken seriously), let’s pause for a moment and remember what Jensen has contributed to our industry with his determination and vision, which laid the foundation that we all work off of today.
Jensen’s statements have shown grace and dignity to his family and the industry. He surely understands the impact.
Now we should be patient and wait for investigations by the board of directors and any government authorities to conclude.
3
268
Lfggggg
Today we are launching @BioDelivera a programmable drug delivery platform that delivers therapies only to diseased cells enabling cures for every disease. 🎯🧪
Less than 3% of an injected therapy reaches diseased cells. The rest ends up in healthy organs. At @BioDelivera we want to change that, our mission is to make every therapy accessible to patients.
Happy to build with @ikeda_trashi this exciting technology!
Reach out at [email protected]
Delivery has always been the bottleneck for drugs in general especially gene therapies - check out BioDelivera from this batch, twins that complete each other's sentences building the future of drug delivery
Jeff Liu retweeted
Introducing NovaAtom-Lite, an all-atom structure prediction model for drug discovery.
It predicts the structures of proteins, nucleic acids, and the molecules they bind, including how they fit together.
NovaAtom-Lite outperforms both IsoDDE and AlphaFold 3 on FoldBench antibody–antigen structure prediction (DockQ ≥ 0.23):
NovaAtom-Lite: 79.07% (n=172)
IsoDDE: 75.58%
AlphaFold 3: 47.90% (n=167)
Our evaluation uses 5 seeds × 5 samples, with the top-1 prediction selected by the model's own ranking score.
Better structure prediction. A stronger starting point for your next experiment.
Live today via Geodesic API and NovaDDE.
🔗 API: platform.geodesiclab.com/
🔗 NovaDDE: agent.geodesiclab.com
🔗 Model Card: geodesiclab.com/news/introdu…
Jeff Liu retweeted
Today we're launching Petrichor (YC F26), a wet lab for frontier AI labs.
We run experiments in parallel and return the data from every step.
Wacky
SCOOP: Isomorphic Labs’ latest fundraise is progressing — with a $50 billion valuation attached.
The Google DeepMind spinout is in talks for ~$5B in new funding, per our sources.
w/ @nmasc_👇
157
Bio apes strong together
Always awesome to meet with founder grinders who's pushing through the night like it needs to happen tomorrow. And honestly it shouldn't feel like a grind when you're literally shaping an alternate universe
1
12
396
Entirely true. Those thinking you gotta hire in the US because they work harder is crazy. Rate of progress is undoubtedly fastest in China by an insane margin.
For an AI-driven biotech founder, the bottleneck is not generating designs. It is verifying them and stacking wet-lab outcome data you can retrain on.
I saw this on China CRO site visits: design throughput is already ahead of assay queues. In my census of 262 funded US/EU biotechs, AI protein and antibody shops skew hybrid (~44%) for that reason. China built the service layer. My estimate from filings: 35–45k CRO in-vitro discovery staff vs 2.5–3.5k in the US. Operators staff 20 chemists in weeks; multiple shifts on one instrument set (my observation). @WuXi_AppTec: US customers = 72% of continuing revenue. @pharmaron: 3,300+ customers; top-20 only 20.1%.
Rule I would run:
• Keep design and interpretation in-house.
• Buy verification by the sample on that capacity until one assay line sits above ~40% utilisation (illustrative US workcell break-even).
• Prefer machine-orderable assays: fixed input, numeric output, public price — @adaptyvbio binding from ~$99–169/design; @Ginkgo ADME-One $199/panel (company figures).
Cheap design makes the wet lab busier, not idle. The scarce seat connects the model, the assay and the next decision. Can't agree more with that @LifeSciVC Bruce Booth’s Oct 30 essay "The Fruits of AI Drug Abundance: Indigestion In The Near Term"
8
693




















